Cambridge Investment Research Advisors Inc. Has $6.70 Million Holdings in SPDR S&P Biotech ETF (XBI)

Cambridge Investment Research Advisors Inc. reduced its position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 16.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 69,916 shares of the exchange traded fund’s stock after selling 13,919 shares during the quarter. Cambridge Investment Research Advisors Inc. owned 0.12% of SPDR S&P Biotech ETF worth $6,703,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. WESPAC Advisors LLC raised its position in shares of SPDR S&P Biotech ETF by 13.2% in the third quarter. WESPAC Advisors LLC now owns 38,011 shares of the exchange traded fund’s stock valued at $3,644,000 after purchasing an additional 4,426 shares during the period. Wells Fargo & Company MN raised its position in shares of SPDR S&P Biotech ETF by 10.0% in the third quarter. Wells Fargo & Company MN now owns 1,716,647 shares of the exchange traded fund’s stock valued at $164,576,000 after purchasing an additional 156,483 shares during the period. Stratos Wealth Partners LTD. raised its position in shares of SPDR S&P Biotech ETF by 9.4% in the third quarter. Stratos Wealth Partners LTD. now owns 15,938 shares of the exchange traded fund’s stock valued at $1,528,000 after purchasing an additional 1,364 shares during the period. Ashfield Capital Partners LLC raised its position in shares of SPDR S&P Biotech ETF by 38.0% in the third quarter. Ashfield Capital Partners LLC now owns 35,228 shares of the exchange traded fund’s stock valued at $3,377,000 after purchasing an additional 9,705 shares during the period. Finally, Private Advisor Group LLC raised its position in shares of SPDR S&P Biotech ETF by 35.4% in the third quarter. Private Advisor Group LLC now owns 24,534 shares of the exchange traded fund’s stock valued at $2,352,000 after purchasing an additional 6,411 shares during the period.

Shares of XBI opened at $80.78 on Friday. SPDR S&P Biotech ETF has a fifty-two week low of $76.37 and a fifty-two week high of $101.55.

WARNING: “Cambridge Investment Research Advisors Inc. Has $6.70 Million Holdings in SPDR S&P Biotech ETF (XBI)” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/11/10/cambridge-investment-research-advisors-inc-has-6-70-million-holdings-in-spdr-sp-biotech-etf-xbi.html.

SPDR S&P Biotech ETF Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Featured Story: Hedge Funds – Risk or Reward?

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply